FDA's 2007 Regulations
In 2007, the FDA established new regulations to improve the consistency and safety of dietary supplements. Manufacturers are required to comply with the new standards by 2010, including making sure the supplements don't contain contaminants or impurities and are properly labeled [source: American Cancer Society].
Alpha Lipoic Acid and Peripheral Neuropathy
Peripheral neuropathy is a condition characterized by pain and numbness in the hands and feet that occurs in patients with diabetes, nerve pressure (from abnormal bone growth or a tumor), vitamin deficiency, kidney or liver disease and alcoholism. Cancer treatment chemicals can also cause it and HIV patients are prone to it [source: Mayo Clinic].
More than 20 percent of diabetic patients develop peripheral neuropathy -- the leading cause of lower limb amputation. Oral and intravenous ALA is approved for use in Germany for treatment of diabetic neuropathy and in the U.S., research has shown that ALA may be helpful in treating nerve damage in diabetics and in cancer patients [source: American Cancer Society].
In a clinical trial, diabetic patients suffering from peripheral neuropathy who were given 200 mg of ALA intravenously for 21 days reported a reduction in pain. A larger study of diabetics with peripheral neuropathy who were injected with 600 mg of ALA a day for three weeks, followed by 12 weeks of oral supplements, also experienced relief [source: Larsen].
A small study in Austria found that more than half of the cancer patients who took ALA after getting the chemotherapy drug oxaliplatin reported an improvement in neuropathy symptoms [source: American Cancer Society]. The National Cancer Institute is currently conducting a phase-3 study on ALA's use in preventing peripheral neuropathy in cancer patients undergoing chemotherapy treatment [source: Higdon, American Cancer Society].
To learn more on how ALA could improve your health, visit the links on the following page.